KRRO vs. HRTX, BMEA, ANNX, LXRX, NGNE, MRSN, CRBP, ESPR, PEPG, and RVNC
Should you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Heron Therapeutics (HRTX), Biomea Fusion (BMEA), Annexon (ANNX), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Mersana Therapeutics (MRSN), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), PepGen (PEPG), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Korro Bio (NASDAQ:KRRO) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, community ranking, dividends, profitability, analyst recommendations, institutional ownership and valuation.
In the previous week, Heron Therapeutics had 21 more articles in the media than Korro Bio. MarketBeat recorded 23 mentions for Heron Therapeutics and 2 mentions for Korro Bio. Korro Bio's average media sentiment score of 1.43 beat Heron Therapeutics' score of 0.55 indicating that Korro Bio is being referred to more favorably in the media.
13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 16.8% of Korro Bio shares are owned by company insiders. Comparatively, 6.4% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Korro Bio presently has a consensus price target of $126.25, suggesting a potential upside of 148.77%. Heron Therapeutics has a consensus price target of $5.50, suggesting a potential upside of 92.98%. Given Korro Bio's higher possible upside, research analysts clearly believe Korro Bio is more favorable than Heron Therapeutics.
Korro Bio has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Korro Bio has a net margin of 0.00% compared to Heron Therapeutics' net margin of -61.28%. Heron Therapeutics' return on equity of 0.00% beat Korro Bio's return on equity.
Heron Therapeutics received 647 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 68.98% of users gave Heron Therapeutics an outperform vote.
Korro Bio has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
Summary
Korro Bio beats Heron Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Korro Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Korro Bio Competitors List
Related Companies and Tools
